| Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... New England Journal of Medicine 375 (24), 2335-2348, 2016 | 1733 | 2016 |
| Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded … A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ... The Lancet 389 (10086), 2287-2303, 2017 | 1171 | 2017 |
| Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis KB Gordon, A Blauvelt, KA Papp, RG Langley, T Luger, M Ohtsuki, ... New England Journal of Medicine 375 (4), 345-356, 2016 | 912 | 2016 |
| Human skin Langerhans cells are targets of dengue virus infection SJL Wu, G Grouard-Vogel, W Sun, JR Mascola, E Brachtel, R Putvatana, ... Nature medicine 6 (7), 816-820, 2000 | 906 | 2000 |
| Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe … A Blauvelt, KA Papp, CEM Griffiths, B Randazzo, Y Wasfi, YK Shen, S Li, ... Journal of the american academy of dermatology 76 (3), 405-417, 2017 | 871 | 2017 |
| Circulating Th17, Th22, and Th1 cells are increased in psoriasis S Kagami, HL Rizzo, JJ Lee, Y Koguchi, A Blauvelt Journal of Investigative Dermatology 130 (5), 1373-1383, 2010 | 830 | 2010 |
| IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice JS Cho, EM Pietras, NC Garcia, RI Ramos, DM Farzam, HR Monroe, ... The Journal of clinical investigation 120 (5), 1762-1773, 2010 | 716 | 2010 |
| Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial D Thaçi, A Blauvelt, K Reich, TF Tsai, F Vanaclocha, K Kingo, M Ziv, ... Journal of the American Academy of Dermatology 73 (3), 400-409, 2015 | 643 | 2015 |
| Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose … D Thaci, EL Simpson, LA Beck, T Bieber, A Blauvelt, K Papp, W Soong, ... The Lancet 387 (10013), 40-52, 2016 | 619 | 2016 |
| Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and … KB Gordon, B Strober, M Lebwohl, M Augustin, A Blauvelt, Y Poulin, ... The Lancet 392 (10148), 650-661, 2018 | 599 | 2018 |
| The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis A Blauvelt, A Chiricozzi Clinical reviews in allergy & immunology 55 (3), 379-390, 2018 | 577 | 2018 |
| Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis EG Harper, C Guo, H Rizzo, JV Lillis, SE Kurtz, I Skorcheva, D Purdy, ... Journal of Investigative Dermatology 129 (9), 2175-2183, 2009 | 570 | 2009 |
| Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials K Reich, KA Papp, A Blauvelt, SK Tyring, R Sinclair, D Thaçi, K Nograles, ... The Lancet 390 (10091), 276-288, 2017 | 533 | 2017 |
| Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection M Zaitseva, A Blauvelt, S Lee, CK Lapham, V Kiaus-Kovrun, H Mostowski, ... Nature medicine 3 (12), 1369-1375, 1997 | 529 | 1997 |
| Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis KA Papp, A Blauvelt, M Bukhalo, M Gooderham, JG Krueger, JP Lacour, ... New England Journal of Medicine 376 (16), 1551-1560, 2017 | 523 | 2017 |
| Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines E Fitch, E Harper, I Skorcheva, SE Kurtz, A Blauvelt Current rheumatology reports 9 (6), 461-467, 2007 | 484 | 2007 |
| Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5 MM Lederman, RS Veazey, R Offord, DE Mosier, J Dufour, M Mefford, ... Science 306 (5695), 485-487, 2004 | 483 | 2004 |
| A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis KA Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, ... British Journal of Dermatology 175 (2), 273-286, 2016 | 472 | 2016 |
| Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) A Wollenberg, A Blauvelt, E Guttman‐Yassky, M Worm, C Lynde, ... British Journal of Dermatology 184 (3), 437-449, 2021 | 410 | 2021 |
| Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial EL Simpson, AS Paller, EC Siegfried, M Boguniewicz, L Sher, ... JAMA dermatology 156 (1), 44-56, 2020 | 403 | 2020 |
